Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
CANCvsBBPETF Comparison
Tema Oncology ETF (CANC) and Virtus LifeSci Biotech Products ETF (BBP) belong to the same industry segment: Tomorrow's Treatments. Both ETFs have the same top 3 sector exposures: and Health Care. CANC is more expensive with a Total Expense Ratio (TER) of 0.99%, versus 0.79% for BBP. CANC is up 4.1% year-to-date (YTD) with +$41M in YTD flows. BBP performs better with 5.62% YTD performance, and +$4M in YTD flows. Run a side-by-side ETF comparison of CANC and BBP below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
CANC vs BBP performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | CANC BBP | -0.94%+2.73% | +4.18%+7.35% | +4.10%+5.62% | +43.76%+41.19% | n/a+72.79% | n/a+54.18% |
| Flows | CANC BBP | +$12M+$4M | +$49M+$16M | +$41M+$4M | +$63M+$19M | -+$19M | -+$9M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | CANC BBP | +23.29%+24.64% | +25.13%+25.49% | n/a+23.37% | n/a+26.10% |
| Max drawdown | CANC BBP | -4.68%-7.42% | -17.26%-17.97% | n/a-25.54% | n/a-38.24% |
| Max drawdown duration | CANC BBP | 16d32d | 80d106d | n/a292d | n/a915d |
CANC | BBP | |
Last sale 3/13/2026 at 1:30 PM | $35.99 | $81.25 |
| Previous close 03/12/2026 | $36.33 | $81.68 |
| Consolidated volume 03/12/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
CANC | BBP | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
CANC | BBP | |
|---|---|---|
| Last price | $35.99 | $81.25 |
| 1D performance | -0.95% | -0.53% |
| AuM | $161.18 M | $50.55 M |
| E/R | 0.99% | 0.79% |
CANC | BBP | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Tema | VIRTUS Investment Partners |
| Benchmark | - | LifeSci Biotechnology Products Index |
| N° of holdings | 46 | 58 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 15, 2023 | December 16, 2014 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the CANC and BBP ETFs performed in 2026?
As of March 12, 2026, CANC is up 4.1% year-to-date (YTD), while BBP has returned 5.62%. That puts BBP better performer ahead so far this year.
Which ETF is attracting more investor money: CANC or BBP?
Year-to-date, the CANC ETF saw +$41M in flows, compared to +$4M for BBP.
Which ETF is more volatile: CANC or BBP?
Over the past year, CANC had a volatility of 25.13%, while BBP experienced 25.49%.
Which ETF is bigger: CANC or BBP?
As of March 12, 2026, CANC holds $161.18 M in assets under management (AUM), while BBP manages $50.55 M.
What sectors do the CANC and BBP ETFs invest in?
CANC leans toward sectors like Health Care. Meanwhile, BBP focuses on Health Care.
What are the top holdings of the CANC ETF and BBP ETF?
CANC top holdings include REVOLUTION MEDICINES INC, BRIDGEBIO PHARMA and NOVARTIS. BBP holds in its top three: DAY ONE BIOPHARMACEUTICALS, DYNAVAX TECHNOLOGIES and AMICUS THERAPEUTICS.
Which ETF is more diversified: CANC or BBP?
CANC holds 56 securities with 56.2% of its assets in the top 15. BBP has 63 securities and a top 15 weight of 30.11%.
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
